Optimization of hapten-peptide labeling for pretargeted immunoPET of bispecific antibody using generator-produced 68Ga

Journal of Nuclear Medicine

Volumn 52, Issue 4, 2011, Pages 555-559

  Karacay, Habibe ^a   Sharkey, Robert M ^a   McBride, William J ^b   Rossi, Edmund A ^c   Chang, Chien Hsing ^b,c   Goldenberg, David M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

^b IMMUNOMEDICS INC   (United States)

^c IBC Pharmaceuticals Inc   (United States)

Author keywords

68Ga; 68Ge 68Ga generator; Bispecific antibody; Pretargeting

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO TYROSYL DEXTRO LYSYL(HISTAMINE SUCCINYLGLYCINE)DEXTRO GLUTAMYL DEXTRO LYSYL(HISTAMINE SUCCINYLGLYCINE)AMINE; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO TYROSYL DEXTRO LYSYL(HISTAMINE SUCCINYLGLYCINE)DEXTRO GLUTAMYL DEXTRO LYSYL(HISTAMINE SUCCINYLGLYCINE)AMINE GA 68; 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID DEXTRO TYROSYL DEXTRO LYSYL(HISTAMINE SUCCINYLGLYCINE)DEXTRO GLUTAMYL DEXTRO LYSYL(HISTAMINE SUCCINYLGLYCINE)AMINE IN 111; BISPECIFIC ANTIBODY; HAPTEN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIBODY LABELING; ARTICLE; COLON CANCER; CONTROLLED STUDY; DRUG TARGETING; DRUG UPTAKE; HUMAN; IMMUNOPOSITRON EMISSION TOMOGRAPHY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; TISSUE DISTRIBUTION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, BISPECIFIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GALLIUM RADIOISOTOPES; HALF-LIFE; HAPTENS; HETEROCYCLIC COMPOUNDS, 1-RING; HT29 CELLS; HUMANS; INDIUM RADIOISOTOPES; ISOTOPE LABELING; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION;

EID: 79954570435     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.083568     Document Type: Article

References (19)

1. Ambrosini V, Campana D, Bodei L, et al. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med. 2010;51:669-673.
2. Ambrosini V, Castellucci P, Rubello D, et al. 68Ga-DOTA-NOC: A new PET tracer for evaluating patients with bronchial carcinoid. Nucl Med Commun.2009;30:281-286.
3. 18F-DOPA PET in medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:46-48.
4. Banerjee SR, Pullambhatla M, Byun Y, et al. 68Ga-labeled inhibitors of prostatespecific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem.2010;53:5333-5341.
5. Baum RP, Prasad V, Muller D, et al. Molecular imaging of HER2-expressing malignant tumors in breast cancer patients using synthetic 111In- or 68Ga-labeled affibody molecules. J Nucl Med. 2010;51:892-897.
6. Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging. 2005;32:478-485.
7. Henze M, Schuhmacher J, Hipp P, et al. PET imaging of somatostatin receptors using 68Ga-DOTA-D-Phe1-Tyr3-octreotide: First results in patients with meningiomas. J Nucl Med. 2001;42:1053-1056. (Pubitemid 32595304)
8. Hoigebazar L, Jeong JM, Choi SY, et al. Synthesis and characterization of nitroimidazole derivatives for 68Ga-labeling and testing in tumor xenografted mice. J Med Chem. 2010;53:6378-6385.
9. Maecke HR, Hofmann M, Haberkorn U. 68Ga-labeled peptides in tumor imaging. J Nucl Med. 2005;46(suppl 1):172S-178S.
10. Meyer GJ, Macke H, Schuhmacher J, Knapp WH, Hofmann M. 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging. 2004;31:1097-1104.
11. Tolmachev V, Velikyan I, Sandstrom M, Orlova AA. HER2-binding Affibody molecule labelled with 68Ga for PET imaging: Direct in vivo comparison with the 111In-labelled analogue. Eur J Nucl Med Mol Imaging. 2010;37:1356-1367.
12. McBride WJ, Zanzonico P, Sharkey RM, et al. Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled hapten-peptide. J Nucl Med. 2006;47: 1678-1688. (Pubitemid 47545036)
13. 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther. 2010;9:1019-1027.
14. Sharkey RM, Karacay H, Vallabhajosula S, et al. Metastatic human colonic carcinoma: Molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology. 2008;246:497-507.
15. Rossi EA, Goldenberg DM, Cardillo TM, McBride WJ, Sharkey RM, Chang CH. Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA.2006;103:6841-6846.
16. Green MA, Welch MJ. Gallium radiopharmaceutical chemistry. Int J Rad Appl Instrum B. 1989;16:435-448. (Pubitemid 19213884)
17. Velikyan I, Beyer GJ, Bergstrom-Pettermann E, Johansen P, Bergstrom M, Langstrom B. The importance of high specific radioactivity in the performance of 68Ga-labeled peptide. Nucl Med Biol. 2008;35:529-536. (Pubitemid 351853426)
18. Velikyan I, Maecke H, Langstrom B. Convenient preparation of 68Ga-based PET-radiopharmaceuticals at room temperature. Bioconjug Chem. 2008;19:569-573. (Pubitemid 351294931)
19. Bauwens M, Chekol R, Vanbilloen H, Bormans G, Verbruggen A. Optimal buffer choice of the radiosynthesis of 68Ga-DOTATOC for clinical application. Nucl Med Commun. 2010;31:753-758.